2020 - Fellow, National Academy of Inventors
2018 - Fellow of the American Association for the Advancement of Science (AAAS)
His primary areas of investigation include Pharmacology, Neuroscience, Endocrinology, Internal medicine and Epilepsy. His study in Pharmacology is interdisciplinary in nature, drawing from both NMDA receptor, AMPA receptor, Kainate receptor, GABAA receptor and Anticonvulsant. He combines subjects such as Postsynaptic potential, Depolarization, Potassium channel and Voltage-dependent calcium channel with his study of Neuroscience.
His Endocrinology study integrates concerns from other disciplines, such as Long-term potentiation, Receptor, Neuroactive steroid and Clonazepam. His work on Excretion, Gout, Denervation and Urine organic acids is typically connected to Succinic semialdehyde dehydrogenase deficiency as part of general Internal medicine study, connecting several disciplines of science. His Epilepsy study incorporates themes from Gabapentin, Channelopathy and Migraine.
The scientist’s investigation covers issues in Neuroscience, Pharmacology, Epilepsy, Internal medicine and Endocrinology. His studies deal with areas such as Depolarization, Kainate receptor and Neurotransmission as well as Neuroscience. The Pharmacology study combines topics in areas such as NMDA receptor, Neuroactive steroid, GABAA receptor and Anticonvulsant, Pentylenetetrazol.
His NMDA receptor research is multidisciplinary, incorporating perspectives in Biophysics, Antagonist and Stereochemistry. His studies in Neuroactive steroid integrate themes in fields like Status epilepticus and Benzodiazepine. His Epilepsy study combines topics in areas such as Voltage-dependent calcium channel and Migraine.
Neuroscience, Epilepsy, Pharmacology, GABAA receptor and Neuroactive steroid are his primary areas of study. His Neuroscience study frequently draws connections between adjacent fields such as Neurotransmission. His Epilepsy study results in a more complete grasp of Psychiatry.
His biological study spans a wide range of topics, including Benzodiazepine, Status epilepticus, Anticonvulsant, Pentylenetetrazol and AMPA receptor. The various areas that he examines in his GABAA receptor study include Convulsant and Ionotropic effect. His Neuroactive steroid research incorporates themes from Allosteric modulator and Endocrinology.
Michael A. Rogawski focuses on Pharmacology, Epilepsy, Neuroscience, GABAA receptor and Neuroactive steroid. He has researched Pharmacology in several fields, including NMDA receptor, Agonist, Status epilepticus, Anticonvulsant and Kainate receptor. His Epilepsy research is under the purview of Psychiatry.
His research integrates issues of Vertebrate and Neurotransmission in his study of Neuroscience. The concepts of his GABAA receptor study are interwoven with issues in Clonazepam, Ionotropic effect, Barbiturate, gamma-Aminobutyric acid and Allosteric modulator. His Neuroactive steroid study combines topics from a wide range of disciplines, such as Endocrinology and Benzodiazepine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The neurobiology of antiepileptic drugs.
Michael A. Rogawski;Wolfgang Löscher.
Nature Reviews Neuroscience (2004)
d-Serine is an endogenous ligand for the glycine site of the N-methyl-d-aspartate receptor
Jean Pierre Mothet;Angèle T. Parent;Angèle T. Parent;Herman Wolosker;Roscoe O. Brady.
Proceedings of the National Academy of Sciences of the United States of America (2000)
Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds.
Michael A. Rogawski;Roger J. Porter.
Pharmacological Reviews (1990)
Glia and epilepsy: excitability and inflammation
Orrin Devinsky;Annamaria Vezzani;Souhel Najjar;Nihal C. De Lanerolle.
Trends in Neurosciences (2013)
Neuroprotective and disease-modifying effects of the ketogenic diet
Maciej Gasior;Michael A. Rogawski;Adam L. Hartman;Adam L. Hartman.
Behavioural Pharmacology (2006)
Molecular Targets for Antiepileptic Drug Development
Brian S. Meldrum;Michael A. Rogawski.
The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions
Michael A Rogawski;Wolfgang Löscher.
Nature Medicine (2004)
The Neuropharmacological Basis for the Use of Memantine in the Treatment of Alzheimer's Disease
Michael A. Rogawski;Gary L. Wenk.
Cns Drug Reviews (2006)
Adjunctive perampanel for refractory partial-onset seizures: Randomized phase III study 304
Jacqueline A. French;Gregory L. Krauss;Victor Biton;David Squillacote.
Colchicine myopathy and neuropathy
Ralph W. Kuncl;Greg Duncan;Danny Watson;Kathy Alderson.
The New England Journal of Medicine (1987)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: